Related Experiment Videos
Selection criteria for placement of left ventricular assist devices
1Division of Cardiac Surgery, College of Physicians and Surgeons, Columbia University, New York, NY.
Insights
Limited heart donors necessitate alternatives for end-stage congestive heart failure patients. Long-term implantable Left Ventricular Assist Devices (LVADs) offer a viable solution, bridging patients to transplantation or serving as permanent support.
Area of Science:
- Cardiology
- Medical Devices
- Surgical Innovation
Background:
- Annual heart donor availability (2,000) is insufficient for the 50,000 patients with end-stage congestive heart failure requiring transplantation.
- The critical shortage of donor hearts has driven the development and adoption of mechanical circulatory support.
- Long-term implantable Left Ventricular Assist Devices (LVADs) have emerged as a crucial therapeutic option.
Purpose of the Study:
- To review the indications and contraindications for implantable LVAD insertion.
- To enhance clinician awareness of the benefits and limitations of long-term LVAD technology.
- To inform clinical practice based on extensive patient experience.
Main Methods:
- Analysis of clinical experience with 29 patients over a 4-year period.
- Evaluation of patient selection criteria for LVAD implantation.
- Review of outcomes and complications associated with long-term LVAD support.
Main Results:
- Long-term implantable LVADs are successfully used as a bridge to transplantation.
- The use of LVADs raises the possibility of permanent device implantation as an alternative to transplantation.
- FDA advisory panel support suggests wider adoption of these devices.
Conclusions:
- Improved clinician awareness of LVAD benefits and limitations is mandated due to increased device availability.
- Careful consideration of indications and contraindications is essential for optimal patient selection.
- LVADs represent a significant advancement in managing end-stage heart failure.
Abstract:
The 2,000 heart donors available annually continue to be inadequate for the 50,000 patients with end-stage congestive heart failure who require heart transplantation to survive. This discrepancy has led to the successful use of long-term implantable LVADs as a bridge to transplantation and has raised the issue of permanent device implantation in lieu of transplantation. The recent support by Food and Drug Administration medical advisory panel for widespread release of an implantable, long-term LVAD as a bridge to transplantation makes more widespread of the devices likely and mandates improved clinician awareness of the benefits and limitations of this new technology. We outline our indications and contraindications for insertion of implantable LVADs based on our 4-year clinical experience with 29 patients.